Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLK2 | Q86UE8 | 5/20 | 0.61 |
| ▸ | PDPK1 | O15530 | 4/20 | 0.61 |
| ▸ | CDK2 | P24941 | 6/20 | 0.59 |
| ▸ | RET | P07949 | 5/20 | 0.59 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.59 |
| ▸ | GSK3B | P49841 | 3/20 | 0.59 |
| ▸ | CDK1 | P06493 | 2/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | KDR | P35968 | 2/20 | 0.59 |
| ▸ | GSK3A | P49840 | 2/20 | 0.59 |
| ▸ | CDK7 | P50613 | 2/20 | 0.59 |
| ▸ | CDK9 | P50750 | 2/20 | 0.59 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.59 |
| ▸ | JAK3 | P52333 | 2/20 | 0.59 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.59 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.59 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.59 |
| ▸ | PLK4 | O00444 | 1/20 | 0.59 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.59 |
| ▸ | AURKA | O14965 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5728094 | 1.00 | TLK2 (0.61) | TLK2PDPK1CDK2RETCCNE1 | |
| SCHEMBL5728098 | 0.81 | MAPT (0.64) | TLK2PDPK1RETGSK3BKDR | |
| SCHEMBL5728101 | 0.81 | MAPT (0.64) | TLK2PDPK1RETGSK3BKDR | |
| SCHEMBL5396502 | 0.80 | SRC (0.56) | PDPK1CDK2RETCCNE1GSK3B | |
| SCHEMBL1851095 | 0.78 | RET (0.67) | CDK2RETCCNE1GSK3BJAK3 | |
| SCHEMBL13080904 | 0.78 | RET (0.67) | CDK2RETCCNE1GSK3BJAK3 | |
| SCHEMBL1851097 | 0.78 | RET (0.67) | CDK2RETCCNE1GSK3BJAK3 | |
| SCHEMBL13080514 | 0.77 | CCNE1 (0.66) | CDK2RETCCNE1GSK3BJAK3 | |
| SCHEMBL5728024 | 0.76 | TLK2 (1.00) | TLK2PDPK1CDK2RETCCNE1 | |
| SCHEMBL5728025 | 0.76 | TLK2 (1.00) | TLK2PDPK1CDK2RETCCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050090541-A1 | Indolinone derivatives and their use in treating disease-states such as cancer | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-04-28 | — | — | US | claimed |
| US-7105563-B2 | Indolinone derivatives and their use in treating disease-states such as cancer | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-09-12 | — | — | US | disclosed |
| EP-1680401-A2 | INDOLINONE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | Schering Aktiengesellschaft (DE) | 2006-07-19 | — | — | EP | disclosed |
| WO-2005040116-A2 | INDOLINONE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-05-06 | — | — | WO | disclosed |
| US-20050090541-A1 | Indolinone derivatives and their use in treating disease-states such as cancer | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090541-A1 | Indolinone derivatives and their use in treating disease-states such as cancer | PDK3, PDK2, PDK4 | TLK2 847/4885PDPK1 4/4885CDK2 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.